Market Place
Sourcing Support
FDA Expands Access to Investigational Drug for Pancreatic Cancer
01 May 2026 //
FIRSTWORD PHARMA
Revolution Issues Legal Threat to Erasca as Rivalry Heats
29 Apr 2026 //
BIOSPACE
RAS Inhibitors Show Antitumor Activity In Cholangiocarcinoma
24 Apr 2026 //
FIRSTWORD PHARMA
Revolution Medicines Presents Daraxonrasib in First-Line at 2026
21 Apr 2026 //
GLOBENEWSWIRE
Revolution Medicines To Unveil Daraxonrasib Phase 3 Results
21 Apr 2026 //
GLOBENEWSWIRE
Revolution Medicines To Unveil Mutant-Targeted RAS(ON) Inhibitor
21 Apr 2026 //
GLOBENEWSWIRE
Revolution to Present Updated Ph 1 Clinical Data for Zoldonrasib
19 Apr 2026 //
FIRSTWORD PHARMA
Revolution Medicines Leads $1.5B Stock Offering Wave
14 Apr 2026 //
ENDPOINTS
Revolution Medicines` Cancer Pill Boosts Late-Stage Survival
13 Apr 2026 //
GLOBENEWSWIRE
Revolution Medicines Starts Ph3 RASolute 303 in Pancreatic Cancer
02 Apr 2026 //
GLOBENEWSWIRE
Revolution, Ascendis Seen As Top Buyout Targets In Biopharma
19 Mar 2026 //
BIOSPACE
Revolution Showcases RAS(ON) Targeted Oncology Pipeline Progress
17 Mar 2026 //
GLOBENEWSWIRE
Tango Therapeutics Reports 2025 Financial & Business Updates
05 Mar 2026 //
GLOBENEWSWIRE
Revolution Medicines Announces 2025 Results and Updates
25 Feb 2026 //
GLOBENEWSWIRE
Revolution Medicines Joins Guggenheim Biotech Summit 2026
04 Feb 2026 //
GLOBENEWSWIRE
Revolution Medicines Doses First Patient in RMC-5127 Trial
29 Jan 2026 //
GLOBENEWSWIRE
Merck Backs Off Revolution After Failing To Agree On Price: WSJ
26 Jan 2026 //
BIOSPACE
Merck in Talks to Buy Drugmaker Revolution Med for up to $32B
10 Jan 2026 //
FINANCIAL TIMES
FDA Grants Breakthrough Therapy Designation to Zoldonrasib
08 Jan 2026 //
GLOBENEWSWIRE
Revolution Medicines To Present At J.P. Morgan Healthcare Conf
05 Jan 2026 //
GLOBENEWSWIRE
Revolution Medicines Starts Rasolute 304 Trial For Daraxonrasib
18 Dec 2025 //
GLOBENEWSWIRE
Revolution Medicines Updates Q3 2025 Financials & Corporate
05 Nov 2025 //
GLOBENEWSWIRE
Revolution Medicines To Share Latest Elironrasib Data For KRAS
22 Oct 2025 //
GLOBENEWSWIRE
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236)
16 Oct 2025 //
GLOBENEWSWIRE
Revolution Medicines Publishes Paper on Zoldonrasib Discovery
24 Jul 2025 //
GLOBENEWSWIRE
FDA Grants Breakthrough Designation to Revolution` Elironrasib
23 Jul 2025 //
GLOBENEWSWIRE
Revolution taps Iambic`s AI models in $25M Discovery Deal
10 Jul 2025 //
FIERCE BIOTECH
Revolution Med, Iambic Collaborate on AI-Driven Drug Discovery
09 Jul 2025 //
GLOBENEWSWIRE
Royalty to pay up to $2B to Revolution Medicines For Cancer Drug
25 Jun 2025 //
GLOBENEWSWIRE
Revolution Wins FDA Breakthrough Tag for Daraxonrasib
23 Jun 2025 //
GLOBENEWSWIRE
Revolution Medicine to Participate in Guggenheim Biotech Conference
29 Jan 2025 //
GLOBENEWSWIRE
Revolution Updates RMC-6236 Study in Advanced Pancreatic Cancer
23 Oct 2024 //
GLOBENEWSWIRE
